Becky Levine

POSITIVE DATA FROM IN VIVO STUDY SHOWS SIGNIFICANT ANTIMICROBIAL ACTIVITY OF OCM™ AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND PSEUDOMONAS AERUGINOSA (PA) IN PORCINE WOUND MODEL

Sarasota, Fla, May 20, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, recently presented in vivo data showing that OCM™ wound matrix alone …

Positive Results from Diabetic Foot Ulcer Clinical Trial Show Dramatic Healing Rate within 12 Weeks or Less Using Novel OMEZA® Platform and Offloading

Sarasota, Fla., March 14, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented positive interim data from a diabetic foot ulcer (DFU) …

OCM™ Wound Platform Demonstrates Antibacterial Activity in Porcine Wound Model, Significantly Reducing Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeruginosa (PA) Compared to Comparator and Control Groups

SARASOTA, Fla., Dec. 8, 2023 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented in vivo data showing that OCM™ alone significantly reduced …

New Clinical Data Demonstrate >90 Percent Area Reduction in Diabetic Foot Ulcers within 12 Weeks or less Using Novel Omeza® Platform plus Offloading

SARASOTA, Fla., Dec. 6, 2023 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today announced interim clinical trial results showing that Omeza® combination therapy …

Omeza Announces New Tranche of Funding and Upcoming Q3 Clinical Activities

SARASOTA, Fla., Sept. 27, 2023 — Omeza, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today announced that it has completed a $6.5 million offering and …

Becky Levine

Our Mission

Omeza Quick Links